Twitter | Pretraživanje | |
Dr. Amy Abernethy
Principal Deputy Commissioner and Acting CIO at
254
Tweetovi
70
Pratim
6.805
Osobe koje vas prate
Tweetovi
Dr. Amy Abernethy proslijedio/la je tweet
Dr. Stephen M. Hahn 30. sij
I had the incredible privilege of addressing the FDA staff today at my first all-hands. I discussed three areas of priority focus – unleashing the power of data, empowering patients and consumers, as well as supporting innovation and competition.
Reply Retweet Označi sa "sviđa mi se"
Dr. Amy Abernethy proslijedio/la je tweet
Robert M Califf 31. sij
Odgovor korisniku/ci @DrAbernethyFDA @FDACommissioner
We will all learn as we go with this. Hats off to Hahn, Abernethy, Woodcock, Shuren, Marks et al for continuing to work on this.
Reply Retweet Označi sa "sviđa mi se"
Dr. Amy Abernethy 21. sij
Odgovor korisniku/ci @DrAbernethyFDA
Recognize 2020 with us & join our public meeting on Feb 24 to discuss opportunities and challenges in product development in the era of individualized therapies. We need your thoughts on how to optimize natural history and registry studies.
Reply Retweet Označi sa "sviđa mi se"
Dr. Amy Abernethy 21. sij
Addressing rare diseases is a priority. Our Office of Orphan Products Development has an incredible technology modernization effort underway to streamline orphan drug designation requests.
Reply Retweet Označi sa "sviđa mi se"
Dr. Amy Abernethy 16. sij
Odgovor korisniku/ci @DrAbernethyFDA
The workshop will discuss evaluation needs, gaps, and approaches for medical XR, with the goal of advancing the evaluation of medical XR devices and applications, accelerating development while ensuring safety and efficacy.
Reply Retweet Označi sa "sviđa mi se"
Dr. Amy Abernethy 16. sij
Medical extended reality is growing and we want to hear from you on best evaluation practices in virtual reality and augmented reality in medicine. Join us at our public workshop on March 5 and share your expertise
Reply Retweet Označi sa "sviđa mi se"
Dr. Amy Abernethy 11. sij
Odgovor korisniku/ci @ScottGottliebMD
FDA’s Technology Modernization Action Plan is a critical step to get us there
Reply Retweet Označi sa "sviđa mi se"
Dr. Amy Abernethy 7. sij
As part of the at , I had the chance to talk to about all the great ways we are looking to improve our data strategy at FDA.
Reply Retweet Označi sa "sviđa mi se"
Dr. Amy Abernethy 7. sij
Odgovor korisniku/ci @DrAbernethyFDA
: We announced a public meeting on Modernizing FDA’s Data Strategy today!
Reply Retweet Označi sa "sviđa mi se"
Dr. Amy Abernethy 7. sij
Thanks to for hosting today’s chat with me at . We had a great conversation on how FDA is working to modernize our data strategy.
Reply Retweet Označi sa "sviđa mi se"
Dr. Amy Abernethy 7. sij
In just a few minutes, I'll be participating in a Q&A at for the . I'm excited to be here, and I hope to see you there! Follow live coverage of the event at .
Reply Retweet Označi sa "sviđa mi se"
Dr. Amy Abernethy 20. pro
Odgovor korisniku/ci @DrAbernethyFDA
The research approach used to study the safety &effectiveness of the vaccine was precedent-setting during a public health emergency & may help create a model for future studies under similar circumstances.
Reply Retweet Označi sa "sviđa mi se"
Dr. Amy Abernethy 20. pro
Late yesterday, we announced the first FDA-approved vaccine for prevention of Ebola virus - a significant public health achievement, that will help protect against Ebola as well as advance U.S. government preparedness efforts.
Reply Retweet Označi sa "sviđa mi se"
Dr. Amy Abernethy 19. pro
Today, FDA issued a draft guidance to provide some clarity regarding evidence needed to demonstrate effectiveness for drugs and biologics.
Reply Retweet Označi sa "sviđa mi se"
Dr. Amy Abernethy 9. pro
Have you seen our new CURE ID app? It’s where health care professionals can report on novel uses of existing medicines for patients with difficult-to-treat infectious diseases, making it easier to spot promising new uses for existing drugs.
Reply Retweet Označi sa "sviđa mi se"
Dr. Amy Abernethy 2. pro
Odgovor korisniku/ci @DrAbernethyFDA
Join the workshop to discuss benefits and risks of using artificial intelligence in radiological imaging, including emerging applications such as AI-guided image acquisition and diagnostic radiology workflow automation.
Reply Retweet Označi sa "sviđa mi se"
Dr. Amy Abernethy 2. pro
We want to hear from you on the use of artificial intelligence (AI) in radiological imaging. Join the FDA at a public workshop on the evolving role of AI in radiological imaging Feb. 25-26, 2020 and comment on the open docket on .
Reply Retweet Označi sa "sviđa mi se"
Dr. Amy Abernethy 26. stu
Odgovor korisniku/ci @DrAbernethyFDA
FDA is concerned that people may mistakenly believe that trying CBD “can’t hurt.” Use of any CBD product should always be discussed with a health care provider. To read more about the potential risks see FDA’s Consumer Update:
Reply Retweet Označi sa "sviđa mi se"
Dr. Amy Abernethy 26. stu
This week, FDA provided an update for consumers about CBD. Importantly, consumers should know there is limited available information about CBD, including about its effects on the body.
Reply Retweet Označi sa "sviđa mi se"
Dr. Amy Abernethy 25. stu
Odgovor korisniku/ci @DrAbernethyFDA
There are number of questions regarding CBD’s safety and there are real risks that need to be considered. There is significant interest in CBD and we must work together to fill in the knowledge gaps about the science, safety and quality of many of these products.
Reply Retweet Označi sa "sviđa mi se"